Related Experiment Video
Updated: Sep 25, 2025
06:18
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
2.9K
Impact of Manufacturing Procedures on CAR T Cell Functionality.
Norihiro Watanabe1, Feiyan Mo1,2, Mary Kathryn McKenna1
1Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, United States.
Frontiers in Immunology
|May 2, 2022
Summary
Chimeric antigen receptor (CAR) T cell therapy shows promise for cancer treatment. Optimizing ex vivo culture conditions is crucial for enhancing CAR T cell function, especially for non-responding patients and solid tumors.
Area of Science:
- Immunotherapy
- Cellular Therapy
- Oncology
Background:
- Chimeric antigen receptor (CAR) T cell therapy has gained significant traction, with six FDA-approved products targeting CD19 and BCMA.
- CAR T cell therapy is a leading cancer treatment, but challenges remain in non-responding patients and solid tumors.
Purpose of the Study:
- This review focuses on the ex vivo manufacturing process of CAR T cells.
- It discusses how ex vivo culture conditions impact CAR T cell functionality.
Main Methods:
- Review of current literature on CAR T cell manufacturing.
- Analysis of the impact of ex vivo culture parameters on CAR T cell function.
Main Results:
- Ex vivo culture conditions significantly influence CAR T cell functionality.
- Optimizing these conditions is key to enhancing therapeutic efficacy.
Conclusions:
- Ex vivo manufacturing is a critical, yet often overlooked, factor in CAR T cell therapy success.
- Further research into optimizing culture conditions can improve outcomes for patients with cancer.
